Triple-Drug attack on brain metastases: new hope for melanoma patients?
NCT ID NCT06712927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of three immune-boosting drugs (relatlimab, nivolumab, and ipilimumab) in 60 people with melanoma that has spread to the brain. The study includes both patients with and without symptoms from their brain tumors. The main goal is to see if the treatment can shrink or stabilize brain tumors for at least 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Relatlimab, nivolumab, and ipilimumab (immune-boosting drugs given by IV)
- What this could lead to
- If it works, this could offer a new treatment option for people with melanoma that has spread to the brain, potentially shrinking tumors and controlling the disease longer.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply to everyone. The drug combination can cause serious immune-related side effects, and it is not yet known if it will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?